Ratings Clinical Laserthermia Systems AB

Equities

CLS B

SE0022049920

Market Closed - Nasdaq Stockholm Other stock markets 10:55:03 2024-05-17 am EDT			5-day change	1st Jan Change
14 ^SEK	+3.58%		-6.32%	-49.28%

May. 14	Clinical Laserthermia Systems AB Enters into an Exclusive Distribution Agreement with MTEC Company	CI
Apr. 30	Clinical Laserthermia Notes US FDA Clearance for ClearPoint's Prism Bone Anchor Accessory	MT

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
One of the major weak points of the company is its financial situation.
Based on current prices, the company has particularly high valuation levels.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
Revenue estimates are regularly revised downwards for the current and coming years.
Over the past four months, analysts' average price target has been revised downwards significantly.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
CLINICAL LASERTHERMIA SYSTEMS AB	-49.28%	10.26M		-
EL.EN. S.P.A.	+2.77%	872M		B+
SISRAM MEDICAL LTD	-18.63%	257M		-
LASEROPTEK CO., LTD.	-31.35%	80.91M	-	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes